US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US5593992A
(en)
|
1993-07-16 |
1997-01-14 |
Smithkline Beecham Corporation |
Compounds
|
US5670527A
(en)
|
1993-07-16 |
1997-09-23 |
Smithkline Beecham Corporation |
Pyridyl imidazole compounds and compositions
|
US6369068B1
(en)
|
1995-06-07 |
2002-04-09 |
Smithkline Beecham Corporation |
Amino substituted pyrimidine containing compounds
|
US5658903A
(en)
|
1995-06-07 |
1997-08-19 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
AP9700912A0
(en)
|
1996-01-11 |
1997-01-31 |
Smithkline Beecham Corp |
Novel cycloalkyl substituted imidazoles
|
ZA97175B
(en)
|
1996-01-11 |
1997-11-04 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds.
|
EP0883402A4
(en)
|
1996-01-11 |
1999-08-11 |
Smithkline Beecham Corp |
NEW CYCLOALKYL-SUBSTITUTED IMIDAZOLES
|
US6372741B1
(en)
|
1996-03-08 |
2002-04-16 |
Smithkline Beecham Corporation |
Use of CSAID™ compounds as inhibitors of angiogenesis
|
JP2000510327A
(ja)
|
1996-03-12 |
2000-08-15 |
スミスクライン・ビーチャム・コーポレイション |
医薬的に活性な化合物の同定方法
|
EP0888335A4
(en)
|
1996-03-13 |
2002-01-02 |
Smithkline Beecham Corp |
NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
|
US6096739A
(en)
|
1996-03-25 |
2000-08-01 |
Smithkline Beecham Corporation |
Treatment for CNS injuries
|
US6235760B1
(en)
|
1996-03-25 |
2001-05-22 |
Smithkline Beecham Corporation |
Treatment for CNS injuries
|
WO1998007425A1
(en)
|
1996-08-21 |
1998-02-26 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
US6096753A
(en)
|
1996-12-05 |
2000-08-01 |
Amgen Inc. |
Substituted pyrimidinone and pyridone compounds and methods of use
|
US6147080A
(en)
|
1996-12-18 |
2000-11-14 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
WO1998028292A1
(en)
|
1996-12-23 |
1998-07-02 |
Smithkline Beecham Corporation |
Novel piperidine containing compounds
|
IL132318A0
(en)
|
1997-04-24 |
2001-03-19 |
Ortho Mcneil Pharm Inc |
Substituted imidazoles useful in the treatment of inflammatory diseases
|
US6514977B1
(en)
|
1997-05-22 |
2003-02-04 |
G.D. Searle & Company |
Substituted pyrazoles as p38 kinase inhibitors
|
JP2002504909A
(ja)
|
1997-06-13 |
2002-02-12 |
スミスクライン・ビーチャム・コーポレイション |
新規な置換ピラゾールおよびピラゾリン化合物
|
AU8154998A
(en)
|
1997-06-19 |
1999-01-04 |
Smithkline Beecham Corporation |
Novel aryloxy substituted pyrimidine imidazole compounds
|
US6093742A
(en)
|
1997-06-27 |
2000-07-25 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of p38
|
TW517055B
(en)
|
1997-07-02 |
2003-01-11 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds
|
AR016294A1
(es)
|
1997-07-02 |
2001-07-04 |
Smithkline Beecham Corp |
Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
|
GB9721437D0
(en)
|
1997-10-10 |
1997-12-10 |
Glaxo Group Ltd |
Heteroaromatic compounds and their use in medicine
|
EP1025102B1
(en)
|
1997-10-20 |
2004-05-19 |
F. Hoffmann-La Roche Ag |
Bicyclic kinase inhibitors
|
US6162613A
(en)
|
1998-02-18 |
2000-12-19 |
Vertex Pharmaceuticals, Inc. |
Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
|
CA2329065A1
(en)
|
1998-05-05 |
1999-11-11 |
Francisco Xavier Talamas |
Pyrazole derivatives as p-38 map kinase inhibitors
|
US6316466B1
(en)
|
1998-05-05 |
2001-11-13 |
Syntex (U.S.A.) Llc |
Pyrazole derivatives P-38 MAP kinase inhibitors
|
MY132496A
(en)
|
1998-05-11 |
2007-10-31 |
Vertex Pharma |
Inhibitors of p38
|
EP1080087A4
(en)
|
1998-05-22 |
2001-11-21 |
Smithkline Beecham Corp |
NEW 2-ALKYL-SUBSTITUTED IMIDAZOLES
|
US6589954B1
(en)
|
1998-05-22 |
2003-07-08 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
NZ508790A
(en)
|
1998-05-22 |
2003-10-31 |
Scios Inc |
Heterocyclic compounds and methods to treat cardiac failure and other disorders
|
US6867209B1
(en)
|
1998-05-22 |
2005-03-15 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
US6448257B1
(en)
|
1998-05-22 |
2002-09-10 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6340685B1
(en)
|
1998-05-22 |
2002-01-22 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
EP1086085A1
(en)
|
1998-06-12 |
2001-03-28 |
Vertex Pharmaceuticals Incorporated |
INHIBITORS OF p38
|
EP1112070B1
(en)
|
1998-08-20 |
2004-05-12 |
Smithkline Beecham Corporation |
Novel substituted triazole compounds
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
JP2002526482A
(ja)
|
1998-09-18 |
2002-08-20 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
p38のインヒビター
|
CA2346665A1
(en)
|
1998-10-07 |
2000-04-13 |
Smithkline Beecham Corporation |
Novel treatment for stroke management
|
WO2000025791A1
(en)
|
1998-11-04 |
2000-05-11 |
Smithkline Beecham Corporation |
Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
IL146105A
(en)
|
1999-04-23 |
2005-09-25 |
Tadeda Pharmaceutical Company |
5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor
|
NZ515285A
(en)
|
1999-05-21 |
2004-01-30 |
Scios Inc |
Indole-type derivatives as inhibitors of p38 kinase
|
WO2001004115A2
(en)
|
1999-07-09 |
2001-01-18 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Novel process for synthesis of heteroaryl-substituted urea compounds
|
US6541477B2
(en)
|
1999-08-27 |
2003-04-01 |
Scios, Inc. |
Inhibitors of p38-a kinase
|
TR200200673T2
(tr)
|
1999-09-17 |
2002-12-23 |
Smithkline Beecham Corporation |
Rinovirüs enfeksiyonlarında csaıd'lerin kullanılması
|
BR0015243A
(pt)
|
1999-10-21 |
2002-07-16 |
Hoffmann La Roche |
Heterociclos de nitrogênio bicìclico substituìdos por heteroalquilamino como inibidores da proteìna cinase p38
|
CN1156477C
(zh)
|
1999-10-21 |
2004-07-07 |
霍夫曼-拉罗奇有限公司 |
作为p38蛋白激酶的抑制剂的烷基氨基-取代的双环氮杂环类化合物
|
US7053099B1
(en)
|
1999-11-23 |
2006-05-30 |
Smithkline Beecham Corporation |
3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
|
EP1248624A4
(en)
|
1999-11-23 |
2003-01-22 |
Smithkline Beecham Corp |
3,4-DIHYDRO- (1H) -CHIRAZOLINE-2-ONES AND THE USE THEREOF AS CSBP / P38 KINASE INHIBITORS
|
EP1233950B1
(en)
|
1999-11-23 |
2005-10-05 |
Smithkline Beecham Corporation |
3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
|
JP2003514900A
(ja)
|
1999-11-23 |
2003-04-22 |
スミスクライン・ビーチャム・コーポレイション |
CSBP/p38キナーゼ阻害剤としての3,4−ジヒドロ−(1H)−キナゾリン−2−オン化合物
|
AU2457201A
(en)
|
1999-12-28 |
2001-07-09 |
Bristol-Myers Squibb Company |
Cytokine, especially tnf-alpha, inhibitors
|
US6906067B2
(en)
|
1999-12-28 |
2005-06-14 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-α expression
|
WO2001064676A2
(en)
|
2000-02-28 |
2001-09-07 |
Scios, Inc. |
INHIBITORS OF p38-α KINASE
|
AR030053A1
(es)
|
2000-03-02 |
2003-08-13 |
Smithkline Beecham Corp |
1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
|
MXPA02012909A
(es)
|
2000-07-24 |
2004-05-05 |
Boehringer Ingelheim Pharma |
Formulaciones mejoradas de dosis oral de 1-(5-ter-butil -2-p-tiolil2h -pirazol-3 -il)-3-(4-2 (2-morfolin-4-il -etoxi) -naftalen -1-il) -urea.
|
PE20020506A1
(es)
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
CA2420286A1
(en)
|
2000-08-31 |
2002-03-07 |
F. Hoffmann-La Roche Ag |
7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
|
ATE298751T1
(de)
|
2000-08-31 |
2005-07-15 |
Hoffmann La Roche |
7-oxopyridoryrimidine
|
EP1337255A4
(en)
|
2000-10-19 |
2006-01-25 |
Smithkline Beecham Corp |
USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
|
WO2002032862A2
(en)
|
2000-10-19 |
2002-04-25 |
Smithkline Beecham Corporation |
Use of p38 inhibitors for the treatment of smoke inhalation
|
HU229471B1
(en)
|
2000-10-23 |
2014-01-28 |
Smithkline Beecham Corp |
2,4,8-trisubstituted-8h-pyrido[2,3d]pyrimidine-7-one compounds, for the treatment of diseases mediated by csbp/p38 kinase
|
ATE318820T1
(de)
|
2000-11-17 |
2006-03-15 |
Bristol Myers Squibb Co |
Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren.
|
AU2002237657A1
(en)
|
2000-11-20 |
2002-06-11 |
Scios Inc. |
Indole-type inhibitors of p38 kinase
|
JP2004533989A
(ja)
|
2000-11-20 |
2004-11-11 |
サイオス インコーポレイテッド |
p38キナーゼのピペリジン/ピペラジン型阻害剤
|
WO2002042292A2
(en)
|
2000-11-20 |
2002-05-30 |
Scios Inc. |
Indol derivative and their use as inhibitors of p38 kinase
|
US20020165286A1
(en)
|
2000-12-08 |
2002-11-07 |
Hanne Hedeman |
Dermal anti-inflammatory composition
|
JP2004521892A
(ja)
|
2000-12-20 |
2004-07-22 |
メルク エンド カムパニー インコーポレーテッド |
(ハロ−ベンゾカルボニル)複素環縮合フェニル系p38キナーゼ阻害剤
|
BRPI0207172B8
(pt)
|
2001-02-12 |
2021-05-25 |
Hoffmann La Roche |
pirido-pirimidinas 6-substituída, sua composição e seu uso, bem como seu intermediário
|
WO2002069892A2
(en)
|
2001-02-28 |
2002-09-12 |
Temple University Of The Commonwealth System Of Higher Education |
METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
|
CA2440211A1
(en)
|
2001-03-09 |
2002-09-19 |
Pfizer Products Inc. |
Benzimidazole anti-inflammatory compounds
|
NZ526528A
(en)
|
2001-03-09 |
2005-02-25 |
Pfizer Prod Inc |
Triazolopyridines as anti-inflammatory agents
|
AU2002303145A1
(en)
|
2001-03-23 |
2002-10-08 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076463A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076984A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
ES2247271T3
(es)
|
2001-04-04 |
2006-03-01 |
Pfizer Products Inc. |
Nuevos benzotriazoles como compuestos antiinflamatorios.
|
KR100861466B1
(ko)
|
2001-04-24 |
2008-10-02 |
메르크 파텐트 게엠베하 |
항혈관형성제 및 TNFα를 이용한 병용 요법
|
WO2002090360A1
(en)
|
2001-05-10 |
2002-11-14 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
EP1392300A1
(en)
|
2001-05-11 |
2004-03-03 |
Vertex Pharmaceuticals Incorporated |
2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
|
ES2289116T3
(es)
|
2001-05-24 |
2008-02-01 |
Eli Lilly And Company |
Nuevos derivados de pirrol como agentes farmaceuticos.
|
JP2005500284A
(ja)
|
2001-06-11 |
2005-01-06 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
P38のイソキノリンインヒビター
|
US7196095B2
(en)
|
2001-06-25 |
2007-03-27 |
Merck & Co., Inc. |
(Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
|
EP1406875B1
(en)
|
2001-06-26 |
2013-07-31 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of tnf-alpha expression
|
ATE360417T1
(de)
|
2001-07-11 |
2007-05-15 |
Boehringer Ingelheim Pharma |
Methode zur behandlung von zytokinvermittelten erkrankungen
|
CA2454913A1
(en)
|
2001-08-20 |
2003-02-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin
|
DE60207273T2
(de)
|
2001-08-30 |
2006-07-20 |
F. Hoffmann-La Roche Ag |
Aminopyrrolverbindungen als entzündungshemmende Wirkstoffe
|
AU2002330031B2
(en)
|
2001-09-21 |
2007-07-05 |
Merck & Co., Inc. |
Androstanes as androgen receptor modulators
|
US7205275B2
(en)
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
AU2002329570A1
(en)
|
2001-10-12 |
2003-01-30 |
Pfizer Products Inc. |
Method of monitoring neuroprotective treatment
|
GB0124938D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124931D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124939D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124928D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124936D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124933D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124932D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
WO2003039534A1
(en)
|
2001-11-08 |
2003-05-15 |
Merck & Co., Inc. |
Compositions and methods for treating osteoporosis
|
JP2005511616A
(ja)
|
2001-11-09 |
2005-04-28 |
サイオス インク. |
嚢胞性繊維症を治療する方法
|
EP1461758A4
(en)
|
2001-12-05 |
2005-10-05 |
Vertex Pharma |
CRYSTAL STRUCTURE OF AN MITOGENIC ACTIVATED PROTEIN, KINASE-ACTIVATED PROTEIN, KINASE-2 AND BINDING POCKETS THEREFOR
|
JP2005511722A
(ja)
|
2001-12-11 |
2005-04-28 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
Birb796bsの投与方法
|
EP1478345A4
(en)
|
2002-01-03 |
2010-11-17 |
Glaxosmithkline Llc |
NOVEL PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR PRODUCTION OF SAID DOSAGE FORMS
|
CA2472475C
(en)
|
2002-01-15 |
2010-05-18 |
Merck & Co., Inc. |
17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
|
DE10203749A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE10203753A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE10203741A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US20040023961A1
(en)
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
EP2258687B1
(en)
|
2002-02-12 |
2012-12-26 |
Glaxosmithkline LLC |
Nicotinamide derivates useful as P38 inhibitors
|
JP4187657B2
(ja)
|
2002-03-07 |
2008-11-26 |
エフ.ホフマン−ラ ロシュ アーゲー |
p38キナーゼインヒビターとしての二環式ピリジン及びピリミジン
|
IL163825A0
(en)
|
2002-03-13 |
2005-12-18 |
Merck & Co Inc |
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
|
AU2003220401A1
(en)
|
2002-03-18 |
2003-10-08 |
Bristol-Myers Squibb Company |
Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
CN1293078C
(zh)
|
2002-04-03 |
2007-01-03 |
霍夫曼-拉罗奇有限公司 |
咪唑并稠合化合物
|
MXPA04009605A
(es)
|
2002-04-05 |
2005-01-11 |
Boehringer Ingelheim Pharma |
Metodo para tratar una hipersecrecion de mucosidad.
|
US20030225089A1
(en)
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
DE10216339A1
(de)
|
2002-04-13 |
2003-10-23 |
Boehringer Ingelheim Pharma |
Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
AU2003229689A1
(en)
|
2002-04-15 |
2003-10-27 |
Glaxo Group Limited |
A method of identifying a modudator for a serine/theronine kinase
|
CA2482022A1
(en)
|
2002-04-19 |
2003-10-30 |
Smithkline Beecham Corporation |
Novel compounds
|
KR101025675B1
(ko)
|
2002-04-23 |
2011-03-30 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
|
AU2003221753A1
(en)
|
2002-04-23 |
2003-11-10 |
Bristol-Myers Squibb Company |
Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
|
US7388009B2
(en)
|
2002-04-23 |
2008-06-17 |
Bristol-Myers Squibb Company |
Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
|
JP4516839B2
(ja)
|
2002-04-30 |
2010-08-04 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アンドロゲン受容体修飾因子としての4−アザステロイド誘導体
|
GB0209891D0
(en)
|
2002-04-30 |
2002-06-05 |
Glaxo Group Ltd |
Novel compounds
|
WO2003097615A1
(en)
|
2002-05-17 |
2003-11-27 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
|
TW200400034A
(en)
|
2002-05-20 |
2004-01-01 |
Bristol Myers Squibb Co |
Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
|
US7008958B2
(en)
|
2002-05-21 |
2006-03-07 |
Bristol-Myers Squibb Company |
2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
|
EP1515727A4
(en)
|
2002-06-11 |
2009-04-08 |
Merck & Co Inc |
INHIBITORS OF P38 KINASE (HALO-BENZO CARBONYL) HETEROBICYCLIC
|
AU2003245989A1
(en)
|
2002-07-09 |
2004-01-23 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
WO2004010929A2
(en)
|
2002-07-25 |
2004-02-05 |
Scios, Inc. |
METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
CA2492112A1
(en)
|
2002-08-06 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
JP2006504667A
(ja)
|
2002-08-08 |
2006-02-09 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
炎症過程に関与するサイトカインの抑制剤としてのフッ素化フェニル−ナフタレニル−尿素化合物
|
DE60309342T2
(de)
|
2002-08-09 |
2007-05-16 |
Eli Lilly And Co., Indianapolis |
Benzimidazole und benzothiazole als inhibitoren der map-kinase
|
US20040110755A1
(en)
|
2002-08-13 |
2004-06-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
|
US20040033222A1
(en)
|
2002-08-14 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors
|
AU2003262911A1
(en)
|
2002-08-29 |
2004-03-19 |
Scios Inc. |
Methods of promoting osteogenesis
|
US7005523B2
(en)
|
2002-08-30 |
2006-02-28 |
Pfizer Inc. |
Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
|
US7037923B2
(en)
|
2002-08-30 |
2006-05-02 |
Pfizer, Inc. |
Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
US20040092547A1
(en)
|
2002-08-30 |
2004-05-13 |
Pfizer Inc |
Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
PA8579601A1
(es)
|
2002-08-30 |
2004-05-07 |
Pfizer Prod Inc |
Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
|
EP1537107A2
(en)
|
2002-08-30 |
2005-06-08 |
Pfizer Products Inc. |
Novel processes and intermediates for preparing triazolo-pyridines
|
US7012143B2
(en)
|
2002-08-30 |
2006-03-14 |
Dombroski Mark A |
Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
US7220763B2
(en)
|
2002-09-03 |
2007-05-22 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
WO2004021988A2
(en)
|
2002-09-05 |
2004-03-18 |
Scios Inc. |
Treatment of pain by inhibition of p38 map kinase
|
WO2004021979A2
(en)
|
2002-09-06 |
2004-03-18 |
Smithkline Beecham Corporation |
PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
|
US7115644B2
(en)
|
2002-09-13 |
2006-10-03 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic compounds
|
AU2003268156A1
(en)
|
2002-09-17 |
2004-04-08 |
Eli Lilly And Company |
Novel pyrazolopyridine derivatves as pharmaceutical agents
|
BR0314783A
(pt)
|
2002-09-27 |
2005-07-26 |
Janssen Pharmaceutica Nv |
Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias
|
AU2003282920A1
(en)
|
2002-10-04 |
2004-05-04 |
Bristol-Myers Squibb Company |
Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
|
US20050288299A1
(en)
|
2002-10-09 |
2005-12-29 |
Mavunkel Babu J |
Azaindole derivatives as inhibitors of p38 kinase
|
EP1560582A4
(en)
|
2002-10-09 |
2008-03-12 |
Scios Inc |
AZAINDOL DERIVATIVES AS INHIBITORS OF THE p38 KINASE
|
AU2003286757B2
(en)
|
2002-11-01 |
2009-06-04 |
Merck Sharp & Dohme Corp. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
DE60327097D1
(de)
|
2002-11-18 |
2009-05-20 |
Hoffmann La Roche |
Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren
|
DE10255040A1
(de)
|
2002-11-26 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Carbaminsäureester mit anticholinerger Wirksamkeit
|
US20040171659A1
(en)
|
2002-12-06 |
2004-09-02 |
Satyanarayana Medicherla |
Methods for treating diabetes
|
US7105537B2
(en)
|
2003-01-28 |
2006-09-12 |
Bristol-Myers Squibb Company |
2-substituted cyclic amines as calcium sensing receptor modulators
|
PL378121A1
(pl)
|
2003-02-05 |
2006-03-06 |
Bristol-Myers Squibb Company |
Sposób wytwarzania pirolotriazynowych inhibitorów kinazy
|
CN101723891A
(zh)
|
2003-02-10 |
2010-06-09 |
沃泰克斯药物股份有限公司 |
通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
|
US7205322B2
(en)
|
2003-02-12 |
2007-04-17 |
Bristol-Myers Squibb Company |
Thiazolidine compounds as calcium sensing receptor modulators
|
EP1596860A4
(en)
|
2003-02-14 |
2009-05-27 |
Smithkline Beecham Corp |
NEW CONNECTIONS
|
DE602004001676T2
(de)
|
2003-02-14 |
2007-08-30 |
Pfizer Products Inc., Groton |
Triazolo-Pyridine als entzündungshemmende Verbindungen
|
PT1611131E
(pt)
|
2003-02-27 |
2010-12-20 |
Palau Pharma Sa |
Derivados de pirazolopiridina
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
JP4617299B2
(ja)
|
2003-03-03 |
2011-01-19 |
アレイ バイオファーマ、インコーポレイテッド |
p38阻害剤及びその使用法
|
US7030112B2
(en)
|
2003-03-25 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
GB0308186D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308185D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308201D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
JP2006523638A
(ja)
|
2003-04-16 |
2006-10-19 |
エフ.ホフマン−ラ ロシュ アーゲー |
キナゾリン化合物
|
MXPA05010975A
(es)
|
2003-04-16 |
2005-11-28 |
Hoffmann La Roche |
Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
|
CN1816529A
(zh)
|
2003-05-01 |
2006-08-09 |
布里斯托尔-迈尔斯.斯奎布公司 |
用作激酶抑制剂的芳基取代的吡唑-酰胺化合物
|
GB0320244D0
(en)
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
JP4832303B2
(ja)
|
2003-05-07 |
2011-12-07 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アンドロゲン受容体モジュレータおよびこれらの使用
|
EP1633714B1
(en)
|
2003-06-04 |
2008-01-23 |
Pfizer Limited |
2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists
|
SI2298743T1
(sl)
|
2003-06-26 |
2012-12-31 |
Novartis Ag |
Inhibitorji p38-kinaze na osnovi 5-ÄŤlenskih heterociklov
|
CA2530025A1
(en)
|
2003-06-30 |
2005-01-20 |
William P. Dankulich |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
CA2530182A1
(en)
|
2003-06-30 |
2005-01-20 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
US20060234931A1
(en)
|
2003-07-17 |
2006-10-19 |
Biggs William H Iii |
Treatment of diseases with kinase inhibitors
|
US7153870B2
(en)
|
2003-07-25 |
2006-12-26 |
Pfizer Inc. |
Nicotinamide derivatives useful as PDE4 inhibitors
|
US20050020587A1
(en)
|
2003-07-25 |
2005-01-27 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
GB0317482D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as pde4 inhibitors
|
GB0317516D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as PDE4 inhibitors
|
GB0317484D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as pde4 inhibitors
|
US20070105114A1
(en)
|
2003-07-29 |
2007-05-10 |
Martha Li |
Biomarkers of cyclin-dependent kinase modulation
|
GB0318814D0
(en)
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
CL2004002050A1
(es)
|
2003-08-13 |
2005-06-03 |
Pharmacia Corp Sa Organizada B |
Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
|
JP2007503393A
(ja)
|
2003-08-22 |
2007-02-22 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
Copd及び肺高血圧の治療方法
|
WO2005023201A2
(en)
|
2003-09-09 |
2005-03-17 |
Medarex, Inc. |
Methods for treating rheumatoid arthritis
|
JP2007505120A
(ja)
|
2003-09-10 |
2007-03-08 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体調節因子としての17−複素環式−4−アザステロイド誘導体。
|
JP4895811B2
(ja)
|
2003-09-11 |
2012-03-14 |
ケミア,インコーポレイテッド |
サイトカイン阻害剤
|
EP1675830A4
(en)
|
2003-09-30 |
2008-08-20 |
Scios Inc |
HETEROCYCLIC AMIDES AND SULFONAMIDES
|
US20060019971A1
(en)
|
2003-09-30 |
2006-01-26 |
Higgins Linda S |
Treatment of cardiovascular disease with inhibitors of p38 kinase
|
US7232824B2
(en)
|
2003-09-30 |
2007-06-19 |
Scios, Inc. |
Quinazoline derivatives as medicaments
|
US7419978B2
(en)
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
AU2004289428B2
(en)
|
2003-11-13 |
2010-06-03 |
F. Hoffmann-La Roche Ag |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
EP1538201A1
(en)
|
2003-12-02 |
2005-06-08 |
F.Hoffmann-La Roche Ag |
Method for the recombinant production and purification of protein kinases
|
GB0329275D0
(en)
|
2003-12-18 |
2004-01-21 |
Merck Sharp & Dohme |
Therapeutic treatment
|
WO2005063715A1
(en)
|
2003-12-18 |
2005-07-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Polymorph of birb 796, a p38map kinase inhibitor
|
KR20060120205A
(ko)
|
2003-12-18 |
2006-11-24 |
화이자 프로덕츠 인코포레이티드 |
p38 MAP 키나제 억제제를 사용하여 동물의 급성 염증을치료하는 방법
|
US20060058296A1
(en)
|
2003-12-24 |
2006-03-16 |
Scios, Inc. |
Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase
|
WO2005065691A1
(en)
|
2003-12-24 |
2005-07-21 |
Scios, Inc. |
Treatment of malignant gliomas with tgf-beta inhibitors
|
US20060052390A1
(en)
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
US20060079461A1
(en)
|
2003-12-24 |
2006-04-13 |
Scios, Inc. |
Treatment of multiple myeloma by inhibition of p38 MAP kinase
|
CN1972925A
(zh)
|
2004-01-30 |
2007-05-30 |
默克专利有限公司 |
双芳基脲类衍生物
|
GB0402140D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
TWI332003B
(en)
|
2004-01-30 |
2010-10-21 |
Lilly Co Eli |
Kinase inhibitors
|
GB0402138D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
GB0402143D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
GB0402137D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
EP1720862A1
(en)
|
2004-02-03 |
2006-11-15 |
Eli Lilly And Company |
Kinase inhibitors
|
US7652146B2
(en)
|
2004-02-06 |
2010-01-26 |
Bristol-Myers Squibb Company |
Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
|
TWI338004B
(en)
|
2004-02-06 |
2011-03-01 |
Bristol Myers Squibb Co |
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
|
EP1718637A2
(en)
|
2004-02-26 |
2006-11-08 |
MERCK PATENT GmbH |
Benzimidazolyl derivatives as kinase inhibitors
|
KR100844864B1
(ko)
|
2004-02-27 |
2008-07-09 |
에프. 호프만-라 로슈 아게 |
헤테로아릴-융합 피라졸로 유도체
|
EP1747202A1
(en)
|
2004-02-27 |
2007-01-31 |
F.Hoffmann-La Roche Ag |
Indazole derivatives and pharmaceutical compositions containing them
|
JP2007528393A
(ja)
|
2004-03-11 |
2007-10-11 |
カイセラ バイオファーマシューティカルズ, インコーポレイテッド |
皮膚の状態および毛の状態を予防および処置するための組成物および方法
|
EP1574501A1
(en)
|
2004-03-11 |
2005-09-14 |
Pfizer Limited |
Quinolinone derivatives, pharmaceutical compositions containing them and their use
|
EP1577292A1
(en)
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylaminoethanol derivatives as beta2 receptor agonists
|
EP1577291A1
(en)
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylethanolamine derivatives as beta-2 agonists
|
AU2005237501A1
(en)
|
2004-04-28 |
2005-11-10 |
Merck Sharp & Dohme Corp. |
Fluorinated 4-azasteroids as androgen receptor modulators
|
WO2005110455A2
(en)
|
2004-05-13 |
2005-11-24 |
Intermune, Inc. |
Combination therapy for treating hepatitis virus infection
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
EP1609789A1
(en)
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
SI1761520T1
(sl)
|
2004-06-23 |
2008-10-31 |
Lilly Co Eli |
Inhibitorji kinaze
|
US7253167B2
(en)
|
2004-06-30 |
2007-08-07 |
Bristol-Myers Squibb Company |
Tricyclic-heteroaryl compounds useful as kinase inhibitors
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
PL1778686T3
(pl)
|
2004-08-12 |
2009-04-30 |
Pfizer |
Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
|
TW200618803A
(en)
|
2004-08-12 |
2006-06-16 |
Bristol Myers Squibb Co |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
US7482359B2
(en)
|
2004-08-25 |
2009-01-27 |
Merck & Co., Inc. |
Androgen receptor modulators
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
AR055271A1
(es)
|
2004-10-05 |
2007-08-15 |
Smithkline Beecham Corp |
Compuesto del acido bifenil carboxilico, composicion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para prepararlo
|
MX2007004248A
(es)
|
2004-10-13 |
2007-06-12 |
Merck Patent Gmbh |
Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
|
MX2007004551A
(es)
|
2004-10-18 |
2007-05-23 |
Amgen Inc |
Compuestos tiadiazol y metodos de uso.
|
JP2008518968A
(ja)
|
2004-10-29 |
2008-06-05 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターとしてのn−(ピリジン−3−イル)−2−フェニルブタンアミド
|
WO2006048266A2
(en)
|
2004-11-04 |
2006-05-11 |
Roche Diagnostics Gmbh |
Gene expression profiling of leukemias with mll gene rearrangements
|
WO2006055302A2
(en)
|
2004-11-04 |
2006-05-26 |
Scios Inc. |
Method of treating myelodysplastic syndromes
|
WO2006051373A1
(en)
|
2004-11-12 |
2006-05-18 |
Pfizer Limited |
Compounds for the treatment of diseases
|
GB0425057D0
(en)
|
2004-11-12 |
2004-12-15 |
Pfizer Ltd |
L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
|
CN101056842A
(zh)
|
2004-11-16 |
2007-10-17 |
默克公司 |
治疗中风的(2r)-2-丙基辛酸前药
|
WO2006058023A2
(en)
|
2004-11-23 |
2006-06-01 |
Merck & Co., Inc. |
Treatment of stroke with histamine h3 inverse agonists or histamine h3 antagonists
|
US20060111416A1
(en)
|
2004-11-24 |
2006-05-25 |
Lane Charlotte A L |
Octahydropyrrolo[3,4-C]pyrrole derivatives
|
US20070224662A1
(en)
|
2004-12-17 |
2007-09-27 |
Jun Luo |
Post-translational modification of proteins in cell-free expression systems
|
US20060154939A1
(en)
|
2004-12-24 |
2006-07-13 |
Boehringer Ingelheim International Gmbh |
Medicaments for the Treatment or Prevention of Fibrotic Diseases
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
PE20061155A1
(es)
|
2004-12-24 |
2006-12-16 |
Boehringer Ingelheim Int |
Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
|
CA2591912C
(en)
|
2004-12-28 |
2013-06-25 |
Aska Pharmaceutical Co., Ltd. |
Pyrimidinylisoxazole derivatives
|
US20060178388A1
(en)
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
ES2351308T3
(es)
|
2005-02-28 |
2011-02-02 |
Merckle Gmbh |
Derivados de imidazol 2-sulfinil- y 2-sulfonil-sustituidos y su uso como inhibidores de citocina.
|
US7759337B2
(en)
|
2005-03-03 |
2010-07-20 |
Amgen Inc. |
Phthalazine compounds and methods of use
|
TW200724142A
(en)
|
2005-03-25 |
2007-07-01 |
Glaxo Group Ltd |
Novel compounds
|
PE20100737A1
(es)
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
EP1868612A4
(en)
|
2005-03-25 |
2010-03-24 |
Glaxo Group Ltd |
NOVEL CONNECTIONS
|
US20060235020A1
(en)
|
2005-04-18 |
2006-10-19 |
Soojin Kim |
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
|
TW200716561A
(en)
|
2005-05-11 |
2007-05-01 |
Array Biopharma Inc |
P38 inhibitors and methods of use thereof
|
US20090074676A1
(en)
|
2005-05-23 |
2009-03-19 |
Smithkline Beecham Corporation |
Inhibition of p38 MAPK For Treatment Of Obesity
|
GB0512429D0
(en)
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
US20070032506A1
(en)
|
2005-07-02 |
2007-02-08 |
Peter Giannousis |
Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
|
US7473784B2
(en)
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
EP1912945A4
(en)
|
2005-08-02 |
2010-06-16 |
Merck Sharp & Dohme |
N- (PYRIDIN-4-YL) -2-PHENYLBUTANAMIDES AS MODULATORS OF THE ANDROGEN RECEPTOR
|
CN102627640A
(zh)
|
2005-08-12 |
2012-08-08 |
默沙东公司 |
可用作p38激酶抑制剂的杂二环化合物
|
US20070049592A1
(en)
|
2005-08-22 |
2007-03-01 |
Geuns-Meyer Stephanie D |
Bis-aryl urea compounds and methods of use
|
WO2007023114A1
(en)
|
2005-08-25 |
2007-03-01 |
F. Hoffmann-La Roche Ag |
P38 map kinase inhibitors and methods for using the same
|
KR101011957B1
(ko)
|
2005-08-25 |
2011-01-31 |
에프. 호프만-라 로슈 아게 |
P38 mαp 키나아제 저해제 및 이의 사용 방법
|
BRPI0615272A2
(pt)
|
2005-08-25 |
2009-08-04 |
Hoffmann La Roche |
inibidores de p38 map kinase e métodos para uso dos mesmos
|
EP1919470A1
(en)
|
2005-08-25 |
2008-05-14 |
F.Hoffmann-La Roche Ag |
FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS
|
JP2009506007A
(ja)
|
2005-08-25 |
2009-02-12 |
エフ.ホフマン−ラ ロシュ アーゲー |
p38MAPキナーゼ阻害剤及びその使用方法
|
CN101268079B
(zh)
|
2005-09-01 |
2011-09-14 |
安斯泰来制药有限公司 |
用于治疗疼痛的哒嗪酮衍生物
|
PT1928821E
(pt)
|
2005-09-21 |
2009-03-10 |
Pfizer Ltd |
Derivados de carboxamida enquanto antagonistas dos receptores muscarínicos
|
JP2009509969A
(ja)
|
2005-09-26 |
2009-03-12 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターとしてのn−(4−オキソ−3,4−ジヒドロキナゾリン−2−イル)ブタンアミド
|
WO2007045989A1
(en)
|
2005-10-20 |
2007-04-26 |
Pfizer Limited |
Pyridyl derivatives useful as h3 ligands
|
PE20070640A1
(es)
|
2005-10-28 |
2007-08-10 |
Lilly Co Eli |
Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38
|
DOP2006000234A
(es)
|
2005-10-28 |
2007-05-31 |
Lilly Co Eli |
Inhibidores de cinasa
|
WO2007056016A2
(en)
|
2005-11-02 |
2007-05-18 |
Kemia, Inc. |
Bisamide cytokine inhibitors
|
WO2007052124A1
(en)
|
2005-11-04 |
2007-05-10 |
Pfizer Limited |
Tetrahydronaphthyridine derivative
|
US8026377B2
(en)
|
2005-11-08 |
2011-09-27 |
Ranbaxy Laboratories, Limited |
Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
TW200738243A
(en)
|
2005-11-15 |
2007-10-16 |
Glaxo Group Ltd |
Novel process and formulations
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
WO2007075896A2
(en)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Heterocyclic cytokine inhibitors
|
ES2389062T3
(es)
|
2006-01-18 |
2012-10-22 |
Amgen, Inc |
Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
|
UA94733C2
(ru)
|
2006-01-31 |
2011-06-10 |
Эррей Биофарма Инк. |
Ингибиторы киназы и способы их использования
|
WO2007091152A1
(en)
|
2006-02-09 |
2007-08-16 |
Pfizer Limited |
Triazolopyridine compounds
|
CA2640665A1
(en)
|
2006-02-10 |
2007-08-16 |
Pfizer Products Inc. |
Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
|
GB0603684D0
(en)
|
2006-02-23 |
2006-04-05 |
Novartis Ag |
Organic compounds
|
CA2645031A1
(en)
|
2006-03-07 |
2007-09-13 |
Bristol-Myers Squibb Company |
Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
|
CA2644421A1
(en)
|
2006-03-07 |
2007-09-13 |
Vertex Pharmaceuticals Incorporated |
Use of vx-702 for treating rheumatoid arthritis
|
MEP9608A
(en)
|
2006-03-20 |
2010-06-10 |
Pfizer Ltd |
Amine derivatives
|
WO2007126871A1
(en)
|
2006-03-29 |
2007-11-08 |
Array Biopharma Inc. |
P38 inhibitors and methods of use thereof
|
JP2009533362A
(ja)
|
2006-04-12 |
2009-09-17 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
キナーゼ媒介性疾患を治療するための複素環式置換ビスアリール尿素のn−オキシド
|
US7745449B2
(en)
|
2006-04-21 |
2010-06-29 |
Amgen Inc. |
Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
|
EP2035005A4
(en)
|
2006-06-09 |
2011-07-06 |
Kemia Inc |
THERAPY BASED ON CYTOKINE INHIBITORS
|
US20090318424A1
(en)
|
2006-06-16 |
2009-12-24 |
Mauro Corsi |
Novel compounds
|
EP2034838A4
(en)
|
2006-06-16 |
2012-01-04 |
Glaxo Group Ltd |
NOVEL CONNECTIONS
|
JP2009542817A
(ja)
|
2006-06-16 |
2009-12-03 |
グラクソ グループ リミテッド |
新規化合物
|
GB0612026D0
(en)
|
2006-06-16 |
2006-07-26 |
Smithkline Beecham Corp |
New use
|
US20090192164A1
(en)
|
2006-06-28 |
2009-07-30 |
Aska Pharmaceutical Co., Ltd. |
Treating agent of inflammatory bowel disease
|
US8207203B2
(en)
|
2006-06-28 |
2012-06-26 |
Aska Pharmaceutical Co., Ltd. |
Pyridylisoxazole derivatives
|
WO2008011032A1
(en)
|
2006-07-17 |
2008-01-24 |
Amgen Inc. |
Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
|
WO2008013823A2
(en)
|
2006-07-26 |
2008-01-31 |
Scios Inc. |
Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide
|
EP2046343B1
(en)
|
2006-07-28 |
2014-05-14 |
Onconova Therapeutics, Inc. |
Formulations of radioprotective alpha, beta unsaturated aryl sulfones
|
PE20080906A1
(es)
|
2006-08-17 |
2008-07-05 |
Kemia Inc |
Derivados heteroarilo como inhibidores de citocina
|
WO2008024391A1
(en)
|
2006-08-22 |
2008-02-28 |
Scios Inc. |
Pharmaceutical formulations of an indole-type derivative and related methods of use
|
WO2008041095A1
(en)
|
2006-10-04 |
2008-04-10 |
Pfizer Limited |
Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
|
WO2008045393A2
(en)
|
2006-10-11 |
2008-04-17 |
Amgen Inc. |
Imidazo- and triazolo-pyridine compounds and methods of use therof
|
JP2010506914A
(ja)
|
2006-10-18 |
2010-03-04 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターとしての2−ヒドロキシ−2−フェニル/チオフェニルプロピオンアミド
|
WO2008049842A2
(en)
|
2006-10-26 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
|
US7943617B2
(en)
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
WO2008071664A1
(en)
|
2006-12-12 |
2008-06-19 |
Smithkline Beecham Corporation |
Nicotinamide derivative used as a p38 kinase inhibitor
|
WO2008071665A1
(en)
|
2006-12-12 |
2008-06-19 |
Smithkline Beecham Corporation |
A nicotinamide derivative useful as p38 kinase inhibitor
|
CN101657460A
(zh)
|
2006-12-13 |
2010-02-24 |
基利得科学公司 |
用于治疗肺炎症和支气管收缩的作为抗炎性信号转导调节剂(AISTM’S)和β-激动剂的相互前药的单磷酸酯
|
EP2102161B1
(en)
|
2006-12-13 |
2012-05-02 |
Pfizer Products Inc. |
Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl- 2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide
|
JP2010513370A
(ja)
|
2006-12-19 |
2010-04-30 |
エフ.ホフマン−ラ ロシュ アーゲー |
ピラゾロ[3,4−d]ピリミジンp38MAPキナーゼインヒビター
|
WO2008079857A1
(en)
|
2006-12-20 |
2008-07-03 |
Bristol-Myers Squibb Company |
Crystalline forms of aryl-substituted pyrazole-amide compounds
|
WO2008089034A2
(en)
|
2007-01-11 |
2008-07-24 |
Kemia, Inc. |
Cytokine inhibitors
|
US8063094B2
(en)
|
2007-02-08 |
2011-11-22 |
Boehringer Ingelheim International Gmbh |
Anti-cytokine heterocyclic compounds
|
JP2010519203A
(ja)
|
2007-02-16 |
2010-06-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
生物活性分子の活性を強化するための組成物及び方法
|
JP4588791B2
(ja)
|
2007-02-16 |
2010-12-01 |
あすか製薬株式会社 |
微粒子油性懸濁液を含む医薬組成物
|
WO2008104473A2
(en)
|
2007-02-28 |
2008-09-04 |
F. Hoffmann-La Roche Ag |
Pyrazolopyriidine derivatives and their use as kinase inhibitors
|
EP2125714B1
(en)
|
2007-03-16 |
2011-06-08 |
Pfizer Limited |
Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide
|
EP2152704A1
(en)
|
2007-05-07 |
2010-02-17 |
Amgen, Inc |
Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
|
AU2008248296B2
(en)
|
2007-05-07 |
2011-12-01 |
Amgen Inc. |
Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators, process for their preparation, and their pharmaceutical use
|
EP2173728A2
(en)
|
2007-07-17 |
2010-04-14 |
Amgen Inc. |
Heterocyclic modulators of pkb
|
WO2009011871A2
(en)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Thiadiazole modulators of pkb
|
US7943658B2
(en)
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
WO2009015000A1
(en)
|
2007-07-25 |
2009-01-29 |
Array Biopharma Inc. |
Pyrazole urea derivatives used as kinase inhibitors
|
CA2699463A1
(en)
|
2007-09-14 |
2009-03-19 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
WO2009038784A1
(en)
|
2007-09-21 |
2009-03-26 |
Amgen Inc. |
Triazole fused heteroaryl compounds as p38 kinase inhibitors
|
WO2009069032A2
(en)
|
2007-11-30 |
2009-06-04 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
WO2009074518A1
(en)
|
2007-12-12 |
2009-06-18 |
Glaxo Group Limited |
Combinations of prolinamide p2x7 modulators with further therapeutic agents
|
GB0724258D0
(en)
|
2007-12-12 |
2008-01-30 |
Glaxo Group Ltd |
Novel combinations
|
WO2009078992A1
(en)
|
2007-12-17 |
2009-06-25 |
Amgen Inc. |
Linear tricyclic compounds as p38 kinase inhibitors
|
US20110166154A1
(en)
|
2008-01-25 |
2011-07-07 |
Bristol-Myers Squibb Company |
Identification of predictive markers of response to dasatinib in human colon cancer
|
CA2716124A1
(en)
|
2008-02-20 |
2009-08-27 |
Boehringer Ingelheim International Gmbh |
Powder inhalers
|
WO2009117156A1
(en)
|
2008-03-21 |
2009-09-24 |
Amgen Inc. |
Pyrazolo-pyrazinone compounds and methods of use thereof
|
JP2009263234A
(ja)
|
2008-04-21 |
2009-11-12 |
Ranbaxy Lab Ltd |
ホスホジエステラーゼタイプiv阻害剤の組成物
|
AR072008A1
(es)
|
2008-06-13 |
2010-07-28 |
Merck & Co Inc |
Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
|
EP2300466B1
(en)
|
2008-06-20 |
2014-08-06 |
Bristol-Myers Squibb Company |
Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
|
EP2307411B1
(en)
|
2008-06-20 |
2014-01-01 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as kinase inhibitors
|
WO2009158450A1
(en)
|
2008-06-25 |
2009-12-30 |
Bristol-Myers Squibb Company |
Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, preparation and use thereof
|
WO2009158446A2
(en)
|
2008-06-25 |
2009-12-30 |
Bristol-Myers Squibb Company |
Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof
|
US8263623B2
(en)
|
2008-07-11 |
2012-09-11 |
Pfizer Inc. |
Triazol derivatives useful for the treatment of diseases
|
EP2328868A1
(en)
|
2008-07-15 |
2011-06-08 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
WO2010007561A1
(en)
|
2008-07-15 |
2010-01-21 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
EP2334673A1
(en)
|
2008-08-29 |
2011-06-22 |
Amgen Inc. |
PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
|
WO2010025201A1
(en)
|
2008-08-29 |
2010-03-04 |
Amgen Inc. |
Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases.
|
WO2010038428A1
(ja)
|
2008-09-30 |
2010-04-08 |
武田薬品工業株式会社 |
タキサン系抗がん剤の置き換え薬
|
EP2206534A1
(de)
|
2008-10-09 |
2010-07-14 |
c-a-i-r biosciences GmbH |
Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten
|
WO2010042649A2
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
|
WO2010042646A1
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof
|
US20110263647A1
(en)
|
2009-01-15 |
2011-10-27 |
Amgen Inc. |
Fluoroisoquinoline substituted thiazole compounds and methods of use
|
JP2012517405A
(ja)
|
2009-02-09 |
2012-08-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
呼吸器及び胃腸の疾患の治療のための新規医薬組成物
|
EP2396302A2
(en)
|
2009-02-13 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
|
JP2012518003A
(ja)
|
2009-02-13 |
2012-08-09 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
2−(2,4−ジフルオロフェニル)−6−(1−(2,6−ジフルオロフェニル)ウレイド)ニコチンアミドの固体形態
|
MX2011008496A
(es)
|
2009-02-17 |
2011-11-18 |
Chiesi Farma Spa |
Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map).
|
GB0902648D0
(en)
|
2009-02-17 |
2009-04-01 |
Argenta Discovery Ltd |
Pharmaceutical compounds and compositions
|
US20120035177A1
(en)
|
2009-04-16 |
2012-02-09 |
Bristol-Myers Squibb Company |
Tablet formulation for p38 inhibitor and method
|
AU2010245072B2
(en)
|
2009-05-05 |
2013-11-28 |
Merck Sharp & Dohme Corp. |
p38 kinase inhibiting agents
|
WO2011025685A1
(en)
|
2009-08-24 |
2011-03-03 |
Merck Sharp & Dohme Corp. |
Jak inhibition blocks rna interference associated toxicities
|
CN104043126A
(zh)
|
2009-10-22 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
轴突变性的调节
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
AU2011232326B2
(en)
|
2010-03-24 |
2014-09-04 |
Onconova Therapeutics, Inc. |
Compositions and methods for prevention and treatment of wounds
|
US9060967B2
(en)
|
2010-03-26 |
2015-06-23 |
Onconova Therapeutics, Inc |
Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
|
GB201009731D0
(en)
|
2010-06-10 |
2010-07-21 |
Pulmagen Therapeutics Inflamma |
Kinase inhibitors
|
CA2803665C
(en)
|
2010-06-28 |
2019-03-05 |
Dieter Dorsch |
2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
|
ES2535656T3
(es)
|
2010-07-05 |
2015-05-13 |
Merck Patent Gmbh |
Derivados de bipiridilo útiles para el tratamiento de enfermedades inducidas por quinasas
|
WO2012031057A1
(en)
|
2010-09-01 |
2012-03-08 |
Bristol-Myers Squibb Company |
Bms- 582949 for the treatment of resistant rheumatic disease
|
WO2012074933A1
(en)
|
2010-11-29 |
2012-06-07 |
Genentech, Inc. |
Methods for detecting neurodegenerative diseases or disorders
|
TWI410425B
(zh)
|
2010-12-03 |
2013-10-01 |
Lilly Co Eli |
唑并[5,4-b]吡啶-5-基化合物
|
AU2012224979B2
(en)
|
2011-03-09 |
2017-01-19 |
Merck Patent Gmbh |
Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses
|
AU2012253615B2
(en)
|
2011-05-09 |
2017-03-02 |
Eip Pharma, Llc |
Compositions and methods for treating Alzheimer's disease
|
ES2552538T3
(es)
|
2011-06-10 |
2015-11-30 |
Chiesi Farmaceutici S.P.A. |
Compuestos que tienen una actividad antagonista de un receptor muscarínico y agonista de un receptor beta-2 adrenérgico
|
EP3111937B1
(en)
|
2011-07-08 |
2020-06-17 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Medicament for treatment of liver cancer
|
PT2780011T
(pt)
|
2011-11-11 |
2018-05-14 |
Lilly Co Eli |
Terapia de combinação para cancro do ovário
|
WO2013086002A1
(en)
|
2011-12-05 |
2013-06-13 |
Cellworks Research India Private Limited |
Compositions, process of preparation of said compositions and method of treating cancer
|
BR112014013178A2
(pt)
|
2011-12-09 |
2017-06-13 |
Chiesi Farm Spa |
composto, composição farmacêutica e uso de um composto
|
CN105968110B
(zh)
|
2011-12-09 |
2018-04-27 |
奇斯药制品公司 |
激酶抑制剂
|
JP6145849B2
(ja)
|
2011-12-09 |
2017-06-14 |
チエシ ファルマスーティシ エス.ピー.エー. |
キナーゼ阻害剤
|
RU2666530C2
(ru)
|
2012-01-12 |
2018-09-11 |
Йейл Юниверсити |
Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
|
KR102477065B1
(ko)
|
2012-03-01 |
2022-12-13 |
어레이 바이오파마 인크. |
1-(3-tert-부틸-1-p-톨릴-1H-피라졸-5-일)-3-(5-플루오로-2-(1-(2-하이드록시에틸)-1H-인다졸-5-일옥시)벤질)우레아 하이드로클로라이드의 결정 형태
|
JP6091593B2
(ja)
|
2012-03-20 |
2017-03-08 |
メレオ バイオファーマ 1 リミテッド |
慢性閉塞性肺疾患の急性増悪の治療におけるピラゾール誘導体の使用
|
JP6267193B2
(ja)
|
2012-05-22 |
2018-01-24 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
置換ジピリジルアミン類及びそれらの使用
|
US20150209337A1
(en)
*
|
2012-07-17 |
2015-07-30 |
Glaxosmithkline Llc |
Nicotinamide derivate in the treatment of acute coronary syndrome
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
WO2014033447A2
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
EP2890701B1
(en)
|
2012-08-29 |
2017-03-29 |
Respivert Limited |
Kinase inhibitors
|
US20150210722A1
(en)
|
2012-08-29 |
2015-07-30 |
Respivert Limited |
Kinase inhibitors
|
US9155747B2
(en)
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
EP2925742B1
(en)
|
2012-11-16 |
2016-10-26 |
Respivert Limited |
Kinase inhibitors
|
KR20150075115A
(ko)
|
2012-11-30 |
2015-07-02 |
에프. 호프만-라 로슈 아게 |
브루톤 티로신 키나제의 억제제
|
US9370527B2
(en)
|
2012-12-28 |
2016-06-21 |
The Regents Of The University Of Michigan |
Amelioration of intestinal fibrosis and treatment of Crohn's disease
|
WO2014134313A1
(en)
|
2013-02-27 |
2014-09-04 |
Array Biopharma Inc. |
Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
GB201305714D0
(en)
|
2013-03-28 |
2013-05-15 |
Ucl Business Plc |
Method
|
EP2981535B8
(en)
|
2013-04-02 |
2021-03-10 |
Oxular Acquisitions Limited |
Urea derivatives useful as kinase inhibitors
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
RU2015151886A
(ru)
|
2013-06-06 |
2017-06-08 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Ингибиторы киназ
|
CA2914457A1
(en)
|
2013-06-06 |
2014-12-11 |
Chiesi Farmaceutici S.P.A. |
Kinase inhibitors
|
EP3004098B1
(en)
|
2013-06-06 |
2017-08-09 |
Chiesi Farmaceutici S.p.A. |
Kinase inhibitors
|
US9707219B2
(en)
|
2013-07-10 |
2017-07-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Losmapimod for use in treating glomerular disease
|
WO2015006752A1
(en)
|
2013-07-12 |
2015-01-15 |
The Regents Of The University Of California |
Combination therapies for malaria
|
US9814728B2
(en)
|
2013-09-20 |
2017-11-14 |
Saint Louis University |
Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
|
WO2015072580A1
(ja)
*
|
2013-11-14 |
2015-05-21 |
学校法人同志社 |
細胞増殖促進または細胞障害抑制による角膜内皮治療薬
|
WO2015092423A1
(en)
|
2013-12-20 |
2015-06-25 |
Respivert Limited |
Urea derivatives useful as kinase inhibitors
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
ES2774249T3
(es)
|
2014-02-14 |
2020-07-20 |
Respivert Ltd |
Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios
|
EP3107897A1
(en)
|
2014-02-19 |
2016-12-28 |
H. Lundbeck A/S |
2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
|
WO2015191996A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
WO2015191986A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
EP3166610B1
(en)
|
2014-07-09 |
2022-11-02 |
Eip Pharma, LLC |
Methods for treating neurologic disorders
|
MA40775A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
|
WO2016051186A1
(en)
|
2014-10-01 |
2016-04-07 |
Respivert Limited |
N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
|
WO2016049677A1
(en)
|
2014-10-03 |
2016-04-07 |
The Walter And Eliza Hall Institute Of Medical Research |
Method of treating cancer
|
WO2016066687A1
(en)
*
|
2014-10-30 |
2016-05-06 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Losmapimod for treating copd
|
WO2016114655A1
(en)
*
|
2015-01-12 |
2016-07-21 |
Ry Pharma B.V. |
Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
|
US10538763B2
(en)
*
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
WO2016124793A1
(en)
|
2015-02-06 |
2016-08-11 |
Association Institut De Myologie |
Treatment of facioscapulohumeral dystrophy
|
TWI703138B
(zh)
|
2015-02-12 |
2020-09-01 |
義大利商吉斯藥品公司 |
具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物
|
WO2016142310A1
(en)
|
2015-03-09 |
2016-09-15 |
F. Hoffmann-La Roche Ag |
Tricyclic dlk inhibitors and uses thereof
|
US20190083470A1
(en)
*
|
2015-03-24 |
2019-03-21 |
The Trustees Of The University Of Pennsylvania |
P38 map kinase inhibitors for treating friedreich's ataxia
|
JP2016193870A
(ja)
|
2015-04-01 |
2016-11-17 |
国立大学法人広島大学 |
慢性骨髄性白血病治療剤
|
US9968604B2
(en)
|
2015-04-16 |
2018-05-15 |
Chiesi Farmaceutici S.P.A. |
Chromene derivatives as phoshoinositide 3-kinases inhibitors
|
JP6515182B2
(ja)
*
|
2015-05-20 |
2019-05-15 |
大日本住友製薬株式会社 |
Wt1抗原ペプチドおよび免疫調節剤の併用
|
WO2016198698A2
(en)
|
2015-06-12 |
2016-12-15 |
Cnic Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii |
P38 inhibitors for the treatment and prophylaxis of liver cancer
|
KR102161364B1
(ko)
|
2015-09-14 |
2020-09-29 |
화이자 인코포레이티드 |
LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
|
JP6889493B2
(ja)
|
2015-10-26 |
2021-06-18 |
イーアイピー ファーマ, エルエルシー |
脳卒中からの回復のための方法および組成物
|
US9427439B1
(en)
|
2015-10-26 |
2016-08-30 |
Eip Pharma, Llc |
Methods and compositions for recovery from stroke
|
EP3383867B1
(en)
|
2015-12-03 |
2021-04-14 |
Chiesi Farmaceutici S.p.A. |
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
|
AR107163A1
(es)
|
2015-12-23 |
2018-03-28 |
Chiesi Farm Spa |
Inhibidores de quinasa
|
US10980787B2
(en)
|
2015-12-24 |
2021-04-20 |
The Doshisha |
Drug for treating or preventing disorder caused by TGF-B signals, and application thereof
|
WO2017117182A1
(en)
|
2015-12-29 |
2017-07-06 |
Board Of Regents, The University Of Texas System |
Inhibition of p38 mapk for the treatment of cancer
|
CA3016308A1
(en)
*
|
2016-02-01 |
2017-08-10 |
President And Fellows Of Harvard College |
Small molecules for mouse satellite cell proliferation
|
US10189844B2
(en)
|
2016-02-04 |
2019-01-29 |
Chiesi Farmaceutici S.P.A. |
Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
|
HUE053648T2
(hu)
|
2016-06-08 |
2021-07-28 |
Support Venture Gmbh |
Gyógyászati kombinációk rák kezelésére
|
GB201611712D0
(en)
|
2016-07-02 |
2016-08-17 |
Hvivo Services Ltd |
Methods and compounds for the treatment or prevention of severe or persistent influenza
|
EP3582781A4
(en)
|
2017-02-15 |
2020-12-09 |
The University of Melbourne |
TREATMENT PROCEDURES
|
PT3691620T
(pt)
*
|
2017-10-05 |
2022-10-06 |
Fulcrum Therapeutics Inc |
Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
WO2019103926A1
(en)
|
2017-11-21 |
2019-05-31 |
Saint Louis University |
P38 inhibitors for the treatment of fshd
|
EP3883597A2
(en)
|
2018-11-20 |
2021-09-29 |
Fulcrum Therapeutics, Inc. |
Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
|
WO2020132004A1
(en)
*
|
2018-12-20 |
2020-06-25 |
Saint Louis University |
Bet inhibitors for modulating dux4 expression in fshd
|
MX2021011118A
(es)
|
2019-03-15 |
2022-01-18 |
Fulcrum Therapeutics Inc |
Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
|
MX2023002853A
(es)
*
|
2020-09-11 |
2023-03-31 |
Arrowhead Pharmaceuticals Inc |
Agentes de arni para inhibir la expresion de dux4, composiciones de dichos agentes, y metodos de uso.
|